Search Results

Crinetics Pharmaceuticals, Inc. announced that on June 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 158,000 shares of its common stock to nine new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan.

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced the appointment of Robert M. Cuddihy, M.D., as senior vice president of Medical Affairs.

Crinetics Pharmaceuticals, Inc. announced that the late-breaking abstracts accepted for presentation at the Endocrine Society’s annual meeting were released earlier than the previously announced embargoed date.

Crinetics Pharmaceuticals, Inc. announced that on May 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 176,000 shares of its common stock to fifteen new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan.

Crinetics Pharmaceuticals, Inc. announced that it will report first quarter 2024 financial results on Thursday, May 9, 2024, after the close of the U.S. financial markets.

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, reported financial results for the first quarter ended March 31, 2024.